Synthesis and biological evaluation of 4-oxoquinoline-3-carboxamides derivatives as potent anti-fibrosis agents. 2014

Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, PR China.

Thirty-one 4-oxoquinoline-3-carboxamides derivatives were synthesized and evaluated for their anti-fibrotic activities by the inhibition of TGF-β1-induced total collagen accumulation and anti-inflammatory activities by the inhibition of LPS-stimulated TNF-α production. Among them, three compounds (10a, 10l and 11g) exhibited potent inhibitory effects on both TGF-β1-induced total collagen accumulation and LPS-stimulated TNF-α production. Furthermore, oral administrations of 10l at a dose of 20 mg/kg/day for 4 weeks effectively alleviated lung inflammation and injury, and decreased lung collagen accumulation in bleomycin-induced pulmonary fibrosis model. Histopathological evaluation of lung tissue confirmed 10l as a potential, orally active agent for the treatment of pulmonary fibrosis.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
August 2012, Archiv der Pharmazie,
Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
December 2014, Bioorganic & medicinal chemistry letters,
Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
November 2016, Bioorganic & medicinal chemistry letters,
Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
July 2015, Organic & biomolecular chemistry,
Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
September 2011, Bioorganic & medicinal chemistry,
Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
January 2023, International journal of molecular sciences,
Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
December 2019, Journal of enzyme inhibition and medicinal chemistry,
Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
December 2019, Journal of enzyme inhibition and medicinal chemistry,
Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
September 2017, European journal of medicinal chemistry,
Jun Zhu, and Lin He, and Liang Ma, and Zhe Wei, and Jiqiang He, and Zhuang Yang, and Yuzhi Pu, and Dong Cao, and Yuzhe Wu, and Mingli Xiang, and Aihua Peng, and Yuquan Wei, and Lijuan Chen
March 2014, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!